AR059636A1 - Metodo y composicion para tratar la enfermedad pulmonar obstructiva cronica - Google Patents

Metodo y composicion para tratar la enfermedad pulmonar obstructiva cronica

Info

Publication number
AR059636A1
AR059636A1 ARP070100795A ARP070100795A AR059636A1 AR 059636 A1 AR059636 A1 AR 059636A1 AR P070100795 A ARP070100795 A AR P070100795A AR P070100795 A ARP070100795 A AR P070100795A AR 059636 A1 AR059636 A1 AR 059636A1
Authority
AR
Argentina
Prior art keywords
pulmonary disease
chronic obstructive
obstructive pulmonary
composition
treat chronic
Prior art date
Application number
ARP070100795A
Other languages
English (en)
Spanish (es)
Inventor
S Kuno
H Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR059636A1 publication Critical patent/AR059636A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP070100795A 2006-02-28 2007-02-27 Metodo y composicion para tratar la enfermedad pulmonar obstructiva cronica AR059636A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77694306P 2006-02-28 2006-02-28

Publications (1)

Publication Number Publication Date
AR059636A1 true AR059636A1 (es) 2008-04-16

Family

ID=38462529

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100795A AR059636A1 (es) 2006-02-28 2007-02-27 Metodo y composicion para tratar la enfermedad pulmonar obstructiva cronica

Country Status (13)

Country Link
US (1) US20070203228A1 (enExample)
EP (1) EP1988905B1 (enExample)
JP (2) JP5377970B2 (enExample)
KR (1) KR101409706B1 (enExample)
CN (1) CN101432002B (enExample)
AR (1) AR059636A1 (enExample)
AU (1) AU2007223469B2 (enExample)
BR (1) BRPI0708362A2 (enExample)
CA (1) CA2642744C (enExample)
MX (1) MX2008011148A (enExample)
NZ (1) NZ571092A (enExample)
TW (1) TWI422368B (enExample)
WO (1) WO2007102446A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0708362A2 (pt) * 2006-02-28 2011-05-24 Sucampo Ag método e composição para o tratamento de doença pulmonar obstrutiva crÈnica
WO2011072383A1 (en) * 2009-12-18 2011-06-23 Apotex Pharmachem Inc. Processes for the purification of lubiprostone
BR112013026644A2 (pt) * 2011-04-19 2016-12-27 Sucampo Ag método para a modulação da atividade de citocina
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2597649B2 (ja) * 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 気管・気管支拡張剤
US5362751A (en) * 1988-05-11 1994-11-08 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Tracheobronchodilator using 16-substituted PGEs
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
JPH0791192B2 (ja) * 1989-11-22 1995-10-04 株式会社上野製薬応用研究所 ガス交換機能不全処置剤
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
PT978284E (pt) * 1997-11-28 2008-10-07 Sucampo Ag Utilização de compostos 15-ceto-prostaglandina-e como antagonistas da endotelina
ATE433754T1 (de) * 2000-04-06 2009-07-15 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält
CA2458471C (en) * 2001-08-31 2012-07-31 Sucampo Ag Prostaglandin analogs as chloride channel opener
JP5294559B2 (ja) * 2003-07-03 2013-09-18 スキャンポ・アーゲー クロライドチャンネルオープナーとしてプロスタグランジンアナログを含む腸溶性組成物
BRPI0708362A2 (pt) * 2006-02-28 2011-05-24 Sucampo Ag método e composição para o tratamento de doença pulmonar obstrutiva crÈnica
BR112013026644A2 (pt) * 2011-04-19 2016-12-27 Sucampo Ag método para a modulação da atividade de citocina

Also Published As

Publication number Publication date
CN101432002B (zh) 2012-04-04
EP1988905B1 (en) 2014-06-04
TW200800161A (en) 2008-01-01
NZ571092A (en) 2010-11-26
JP2013209429A (ja) 2013-10-10
JP2009528259A (ja) 2009-08-06
EP1988905A2 (en) 2008-11-12
AU2007223469B2 (en) 2012-06-07
KR20080104024A (ko) 2008-11-28
CA2642744A1 (en) 2007-09-13
MX2008011148A (es) 2008-09-08
BRPI0708362A2 (pt) 2011-05-24
CN101432002A (zh) 2009-05-13
WO2007102446A3 (en) 2008-04-03
TWI422368B (zh) 2014-01-11
AU2007223469A1 (en) 2007-09-13
JP5377970B2 (ja) 2013-12-25
US20070203228A1 (en) 2007-08-30
CA2642744C (en) 2015-02-24
WO2007102446A2 (en) 2007-09-13
KR101409706B1 (ko) 2014-06-20

Similar Documents

Publication Publication Date Title
BR112013021236A2 (pt) composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
CY1111190T1 (el) Παραγωγα μαλεϊμιδιου, φαρμακευτικες συνθεσεις και μεθοδοι για την θεραπεια καρκινου
BR112012009215A2 (pt) "terapia combinada contra o cancer com compostos inibidores de hsp90"
BRPI0606690A2 (pt) composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
AR060089A1 (es) Tratamiento del dolor
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
BR112015003109A2 (pt) Composto, composição, uso de um composto, e, métodos para tratar ou prevenir um distúrbio, condição ou doença e para tratar diabetes mellitus tipo 2.
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
BR112013027034A8 (pt) "compostos para o tratamento de transtornos neuropsiquiátricos."
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
MX2009010450A (es) El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento.
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
BR112012006010A2 (pt) composto de glicina
MX385354B (es) Sales de xantilio 3,6-disustituidas.
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
BR112012031634A2 (pt) composto, composição farmacêutica, uso de um composto, e método para tratar um paciente que sofre de ou susceptível a um distúrbio
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren

Legal Events

Date Code Title Description
FB Suspension of granting procedure